VanEck Biotech ETF (BBH)
Performance
The fund's own total return, a year on average over the longer periods; volatility is the yearly standard deviation of its returns.
Volatility 19.8% over one year, 17.4% over three; Sharpe ratio over three years 0.71.
Largest components
| AMGNAmgen Inc | 15.76% | Healthcare | |
| GILDGilead Sciences Inc | 14.67% | Healthcare | |
| VRTXVertex Pharmaceuticals Inc | 7.94% | Healthcare | |
| MRNAModerna Inc | 7.28% | Healthcare | |
| REGNRegeneron Pharmaceuticals Inc | 6.63% | Healthcare | |
| NTRANatera Inc | 4.69% | Healthcare | |
| IQVIQVIA Holdings Inc | 4.42% | Healthcare | |
| ARGXargenx NV ADR | 4.12% | Healthcare | |
| ILMNIllumina Inc | 4.05% | Healthcare | |
| RVMDRevolution Medicines Inc | 3.59% | Healthcare |
Sectors
Regions
Asset classes
About the fund
- Issuer
- VanEck
- Since
- 2011-12-20
- Listed on
- NASDAQ
- ISIN
- US92189F7261
- Turnover
- 18% a year
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
From the market data provider's fund data, read 2026-10-19. Returns are the fund's own; past returns say nothing certain about future ones. None of this is advice.